NCT06810583View on ClinicalTrials.gov

A Prospective Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk Leukemia

PHASE1RecruitingINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

May 22, 2025

Primary Completion Date

September 30, 2028

Study Completion Date

September 30, 2030

Conditions
LeukemiaAcute Myeloid LeukemiaLymphoblastic Leukemia in Children
Interventions
DRUG

Dalbavancin

3 doses of q28 days dalbavancin (12 weeks).

DRUG

Fluoroquinolone (either ciprofloxacin or levofloxacin at the discretion of the treating clinician)

28 days dalbavancin plus fluoroquinolone (either ciprofloxacin or levofloxacin at the discretion of the treating clinician) for up to 3 doses (12 weeks).

Trial Locations (1)

38105

RECRUITING

St. Jude Children's Research Hospital, Memphis

All Listed Sponsors
lead

St. Jude Children's Research Hospital

OTHER

NCT06810583 - A Prospective Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk Leukemia | Biotech Hunter | Biotech Hunter